Jim Cramer's top 10 things to watch in the stock market Tuesday

Novo Nordisk shares plummeted over 20% after cutting full-year guidance, citing competition from compounded GLP-1s, a factor that also impacted Eli Lilly. In major M&A, Union Pacific agreed to acquire Norfolk Southern for $85 billion, setting the stage for significant rail industry consolidation. Corporate earnings were mixed, with UnitedHealth reporting a dramatic guide down and Merck falling on lower revenue and a $3 billion cost-cutting plan, while Boeing gained on improved deliveries and reduced losses, contributing to a positive market open.

Analysis

Significant divergence is apparent across sectors, with company-specific events heavily influencing stock performance despite a backdrop of record highs for the S&P 500. The healthcare sector is under considerable pressure; Novo Nordisk (NVO) shares plummeted over 20% after cutting its full-year guidance and citing competition from "persistent use of compounded GLP-1s," creating a negative ripple effect that saw competitor Eli Lilly (LLY) fall 4%. Adding to the sector's woes, UnitedHealth (UNH) issued a significant guidance reduction and faces a DOJ investigation, casting doubt on its 2026 growth forecast. Similarly, Merck (MRK) dropped 4% after its first quarterly revenue miss since 2021 and the announcement of a $3 billion cost-cutting initiative ahead of the 2028 Keytruda patent expiration. In contrast, the industrial sector saw positive catalysts. Boeing (BA) shares rose nearly 1% after reducing quarterly losses and reporting its highest aircraft deliveries since 2018, with management targeting 2025 as a "turnaround year." A landmark M&A deal emerged in the rail industry with Union Pacific's (UNP) $85 billion agreement to acquire Norfolk Southern (NSC), a move poised to create the first U.S. coast-to-coast freight operator and potentially spur further consolidation. In technology, Nvidia's (NVDA) order for 300,000 China-specific H20 chips signals a proactive strategy to navigate geopolitical trade issues. Consumer goods giant Procter & Gamble (PG) posted strong earnings and revenue but guided for a $1 billion future drag from tariffs and higher costs, indicating potential margin pressure ahead.

Key Decisions for Investors

• Re-evaluate exposure to GLP-1 drug manufacturers like Novo Nordisk and Eli Lilly, as the material impact from compounded drugs introduces a significant, newly quantified risk to forward growth projections.
• Exercise caution with large-cap healthcare stocks facing distinct headwinds; UnitedHealth's combination of a guidance cut and a DOJ investigation warrants scrutiny, while Merck's revenue miss and restructuring highlight patent cliff risks.
• Monitor the regulatory approval process for the Union Pacific-Norfolk Southern merger, as its outcome will have profound structural implications for the entire rail sector and its competitors.
• For Boeing, investors should watch for sustained improvements in operational metrics like deliveries and cash flow to validate that the 2025 turnaround target is on track.
• Given the flagged headwinds of tariffs and commodity costs at Procter & Gamble, investors should assess the potential for margin compression in the consumer staples sector despite current top-line strength.